Rapamycin versus intermittent feeding: Dissociable effects on physiological and behavioral outcomes when initiated early and late in life

Academic Article

Abstract

  • © The Author 2015. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. Rapamycin, an inhibitor of the mammalian target of rapamycin pathway, has been shown to increase mammalian life span; less is known concerning its effect on healthspan. The primary aim of this study was to examine rapamycin's role in the alteration of several physiological and behavioral outcomes compared with the healthspan-inducing effects of intermittent feeding (IF), another life-spanenhancing intervention. Male Fisher 344 × Brown Norway rats (6 and 25 months of age) were treated with rapamycin or IF for 5 weeks. IF and rapamycin reduced food consumption and body weight. Rapamycin increased relative lean mass and decreased fat mass. IF failed to alter fat mass but lowered relative lean mass. Behaviorally, rapamycin resulted in high activity levels in old animals, IF increased levels of "anxiety" for both ages, and grip strength was not significantly altered by either treatment. Rapamycin, not IF, decreased circulating leptin in older animals to the level of young animals. Glucose levels were unchanged with age or treatment. Hypothalamic AMPK and pAMPK levels decreased in both older treated groups. This pattern of results suggests that rapamycin has more selective and healthspan-inducing effects when initiated late in life.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Carter CS; Khamiss D; Matheny M; Toklu HZ; Kirichenko N; Strehler KYE; Tümer N; Scarpace PJ; Morgan D
  • Start Page

  • 866
  • End Page

  • 875
  • Volume

  • 71
  • Issue

  • 7